Dupixent
(Dupilumab)Dosage & Administration
DUPIXENT is administered by subcutaneous injection.
| Body Weight | Initial and Subsequent Dosage |
|---|---|
| 5 to less than 15 kg | 200 mg (one 200 mg injection) every 4 weeks (Q4W) |
| 15 to less than 30 kg | 300 mg (one 300 mg injection) every 4 weeks (Q4W) |
| Body Weight | Initial Loading Dose | Subsequent DosageQ2W – every 2 weeks; Q4W – every 4 weeks |
|---|---|---|
| 15 to less than 30 kg | 600 mg (two 300 mg injections) | 300 mg Q4W |
| 30 to less than 60 kg | 400 mg (two 200 mg injections) | 200 mg Q2W |
| 60 kg or more | 600 mg (two 300 mg injections) | 300 mg Q2W |
| Initial Loading Dose | Subsequent Dosage |
|---|---|
| 400 mg (two 200 mg injections) | 200 mg every 2 weeks (Q2W) |
| Or | |
| 600 mg (two 300 mg injections) | 300 mg every 2 weeks (Q2W) |
Dosage for patients with oral corticosteroid-dependent asthma or with co-morbid moderate-to-severe atopic dermatitis or adults with co-morbid chronic rhinosinusitis with nasal polyps | |
| 600 mg (two 300 mg injections) | 300 mg every 2 weeks (Q2W) |
| Body Weight | Initial Dose and Subsequent Dosage |
|---|---|
| 15 to less than 30 kg | 300 mg every 4 weeks (Q4W) |
| ≥30 kg | 200 mg every 2 weeks (Q2W) |
For pediatric patients 6 to 11 years old with asthma and co-morbid moderate-to-severe atopic dermatitis, follow the recommended dosage as per Table 2 which includes an initial loading dose.
| Body Weight | Recommended Dosage in Adult and Pediatric Patients 1 Year and Older, Weighing At Least 15 kg |
|---|---|
| 15 to less than 30 kg | 200 mg every 2 weeks (Q2W) |
| 30 to less than 40 kg | 300 mg every 2 weeks (Q2W) |
| 40 kg or more | 300 mg every week (QW) |
| Body Weight | Initial Loading Dose | Subsequent Dosage |
|---|---|---|
| 30 to less than 60 kg | 400 mg (two 200 mg injections) | 200 mg Q2W |
| 60 kg or more | 600 mg (two 300 mg injections) | 300 mg Q2W |
Recommended dosage for adult patients is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week (Q2W). Use DUPIXENT in combination with a tapering course of oral corticosteroids.
By using PrescriberAI, you agree to the AI Terms of Use.
Dupixent Prescribing Information
| Indications and Usage, Chronic Rhinosinusitis with Nasal Polyps | 09/2024 |
| Indications and Usage, Chronic Obstructive Pulmonary Disease | 09/2024 |
| Indications and Usage, Chronic Spontaneous Urticaria | 04/2025 |
| Indications and Usage, Bullous Pemphigoid | 06/2025 |
| Dosage and Administration, Chronic Rhinosinusitis with Nasal Polyps | 09/2024 |
| Dosage and Administration, Chronic Obstructive Pulmonary Disease | 09/2024 |
| Dosage and Administration, Chronic Spontaneous Urticaria | 04/2025 |
| Dosage and Administration, Bullous Pemphigoid | 06/2025 |
| Dosage and Administration, Missed Doses | 06/2025 |
| Warnings and Precautions, Hypersensitivity | 06/2025 |
| Warnings and Precautions, Conjunctivitis and Keratitis | 06/2025 |
| Warnings and Precautions | 04/2025 |
| Warnings and Precautions | 09/2024 |
DUPIXENT is an interleukin-4 receptor alpha antagonist indicated:
for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.
as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.
as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).
for the treatment of adult patients with prurigo nodularis (PN).
as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment.
for the treatment of adult patients with bullous pemphigoid (BP).
DUPIXENT is administered by subcutaneous injection.
Recommended dosage is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every 2 weeks (Q2W).
| Body Weight | Initial and Subsequent Dosage |
|---|---|
| 5 to less than 15 kg | 200 mg (one 200 mg injection) every 4 weeks (Q4W) |
| 15 to less than 30 kg | 300 mg (one 300 mg injection) every 4 weeks (Q4W) |
| Body Weight | Initial Loading Dose | Subsequent DosageQ2W – every 2 weeks; Q4W – every 4 weeks |
|---|---|---|
| 15 to less than 30 kg | 600 mg (two 300 mg injections) | 300 mg Q4W |
| 30 to less than 60 kg | 400 mg (two 200 mg injections) | 200 mg Q2W |
| 60 kg or more | 600 mg (two 300 mg injections) | 300 mg Q2W |
| Initial Loading Dose | Subsequent Dosage |
|---|---|
| 400 mg (two 200 mg injections) | 200 mg every 2 weeks (Q2W) |
| Or | |
| 600 mg (two 300 mg injections) | 300 mg every 2 weeks (Q2W) |
Dosage for patients with oral corticosteroid-dependent asthma or with co-morbid moderate-to-severe atopic dermatitis or adults with co-morbid chronic rhinosinusitis with nasal polyps | |
| 600 mg (two 300 mg injections) | 300 mg every 2 weeks (Q2W) |
| Body Weight | Initial Dose and Subsequent Dosage |
|---|---|
| 15 to less than 30 kg | 300 mg every 4 weeks (Q4W) |
| ≥30 kg | 200 mg every 2 weeks (Q2W) |
For pediatric patients 6 to 11 years old with asthma and co-morbid moderate-to-severe atopic dermatitis, follow the recommended dosage as per Table 2 which includes an initial loading dose.
| Body Weight | Recommended Dosage in Adult and Pediatric Patients 1 Year and Older, Weighing At Least 15 kg |
|---|---|
| 15 to less than 30 kg | 200 mg every 2 weeks (Q2W) |
| 30 to less than 40 kg | 300 mg every 2 weeks (Q2W) |
| 40 kg or more | 300 mg every week (QW) |
| Body Weight | Initial Loading Dose | Subsequent Dosage |
|---|---|---|
| 30 to less than 60 kg | 400 mg (two 200 mg injections) | 200 mg Q2W |
| 60 kg or more | 600 mg (two 300 mg injections) | 300 mg Q2W |
Recommended dosage for adult patients is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week (Q2W). Use DUPIXENT in combination with a tapering course of oral corticosteroids.
DUPIXENT is a clear to slightly opalescent, colorless to pale yellow solution in a:
Single-dose pre-filled syringe with needle shield as:
- Injection: 300 mg/2 mL (150 mg/mL)
- Injection: 200 mg/1.14 mL (175 mg/mL)
Single-dose pre-filled pen as:
- Injection: 300 mg/2 mL (150 mg/mL)
- Injection: 200 mg/1.14 mL (175 mg/mL)
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy.
Healthcare providers and patients may call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/ to enroll in or to obtain information about the registry.
DUPIXENT is contraindicated in patients who have known hypersensitivity to dupilumab or any excipients of DUPIXENT